source
- Phase 1 trial of HS-10504 shows encouraging responses in EGFR C797S mutant lung cancerHS-10504, an investigational therapy, was evaluated in a Phase 1 study in patients with non-small cell lung cancer harboring the EGFR C797S mutation after progression on prior tyrosine kinase inhib…
- Pharma's reputation among patient groups edges up to 57% but access and pricing concerns lingerPatient groups surveyed by research firm PatientView gave drugmakers a 57% “good” or “excellent” reputation rating, the highest level since 2023. The survey covered more than 2,400 groups in 35 cou…